Precision BioSciences, Inc. (DTIL) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation for its gene therapy candidate PBGENE-DMD for the treatment of Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
With this designation, Precision may be eligible to receive a Priority Review Voucher if PBGENE-DMD is approved by the FDA. This voucher can be used to shorten the FDA review time for a different product or sold to another company.
Final IND-enabling toxicology studies of PBGENE-DMD are underway with initial data expected in 2026. "Our first-in-class PBGENE-DMD program, which leverages the differentiated capabilities of our ARCUS gene editing platform to excise exons 45-55 of the dystrophin gene, holds the potential to drive meaningful improvement and durable functional benefit over time for up to 60% of patients with DMD," said Cindy Atwell, Chief Development and Business Officer at Precision BioSciences.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.